Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.51 |
| ▸ | AR | P10275 | 12/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13909410 | 0.96 | MRGPRX4 (0.52) | MRGPRX4ARROCK2ALDH1A1LMNA | |
| SCHEMBL4173921 | 0.96 | MRGPRX4 (0.52) | MRGPRX4ARROCK2ALDH1A1LMNA | |
| SCHEMBL13909408 | 0.93 | AR (0.48) | MRGPRX4ARROCK2ALDH1A1 | |
| SCHEMBL4167637 | 0.93 | AR (0.48) | MRGPRX4ARROCK2ALDH1A1 | |
| SCHEMBL13909250 | 0.88 | AR (0.48) | ARALDH1A1LMNAGAA | |
| SCHEMBL4180793 | 0.88 | AR (0.48) | ARALDH1A1LMNAGAA | |
| SCHEMBL13909244 | 0.87 | AR (0.54) | ARALDH1A1LMNAGAA | |
| SCHEMBL4170436 | 0.87 | AR (0.54) | ARALDH1A1LMNAGAA | |
| SCHEMBL14144349 | 0.87 | AR (0.54) | ARALDH1A1LMNAGAA | |
| SCHEMBL14144260 | 0.87 | AR (0.51) | ARALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | NR5A1, CYP19A1, GPER1 | MRGPRX4 367/4885AR 145/4885ROCK2 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.